Boundless Bio (BOLD) risk factors

Item 1A of every Boundless Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open BOLD in Gloom →

Boundless Bio's chart, financials and news, free in your browser.Open BOLD in Gloom →

FY2025 10-K risk factors
90 risks9 new6 dropped18 reworded
Boundless Bio faces substantial lease obligations and concentrates pipeline efforts on BBI-940 after halting trial enrollments.
Filed Mar 09, 2026
FY2024 10-K risk factors
87 risks
Boundless Bio faces high risks as an unproven clinical-stage oncology company reliant on ecDNA technology. The company lacks commercial products, has never generated revenue, and requires substantial outside capital. Development of ecDTx therapies depends heavily on third-party manufacturers, diagnostic development, and successful patient clinical trials.
Filed Mar 27, 2025